Adding Johnson & Johnson's Zytiga to standard hormone therapy reduced by nearly 40 percent the chance of death for men newly diagnosed with high-risk prostate cancer that had spread to other parts of the body, according to new trial results.

https://www.reuters.com/article/us-h...-idUSKBN18U0GL